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Diabetes is a major cause of chronic kidney disease, and
oral antidiabetic drugs are the mainstay of therapy for
most patients with Type 2 diabetes. Here we evaluated
their role on renal outcomes by using a national Veterans
Administration database to assemble a retrospective cohort
of 93,577 diabetic patients who filled an incident oral
antidiabetic drug prescription for metformin, sulfonylurea,
or rosiglitazone, and had an estimated glomerular filtration
rate (eGFR) of 60ml/min or better. The primary composite
outcome was a persistent decline in eGFR from baseline of
25% or more (eGFR event) or a diagnosis of end-stage renal
disease (ESRD). The secondary outcome was an eGFR event,
ESRD, or death. Sensitivity analyses included using a more
stringent definition of the eGFR event requiring an eGFR
o60ml/min per 1.73m
2 in addition to the 25% or more
decline; controlling for baseline proteinuria thereby
restricting data to 15,065 patients; and not requiring
persistent treatment with the initial oral antidiabetic drug.
Compared to patients using metformin, sulfonylurea users
had an increased risk for both the primary and the secondary
outcome, each with an adjusted hazard ratio of 1.20. Results
of sensitivity analyses were consistent with the main findings.
The risk associated with rosiglitazone was similar to
metformin for both outcomes. Thus, compared to metformin,
oral antidiabetic drug treatment with sulfonylureas
increased the risk of a decline in eGFR, ESRD, or death.
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Chronic kidney disease (CKD) is a major public health
problem. CKD prevalence is increasing worldwide,
1 partly
related to the epidemic of obesity and Type 2 diabetes
mellitus (DM). In the United States, diabetes accounts for
45% of incident end-stage renal disease (ESRD).
2 In 2006,
the US federal government estimated cost was $23 billion for
ESRD treatment, and the corresponding CKD treatment cost
was $49 billion.
2 Patients with CKD have an increased risk
of premature death,
3,4 which is further increased by the
presence of DM.
A number of randomized clinical trials have shown that
control of hyperglycemia,
5–8 blood pressure, and blockade
of the renin–angiotensin–aldosterone system
9,10 can slow the
progression of diabetic kidney disease. Most previous studies
focused on the effect of achieving glycemic targets
5–8 on CKD
progression regardless of the oral antidiabetic drug (OAD)
used, or on the effect of OADs on proteinuria (an early
marker of the development of diabetic kidney disease).
11,12
Few studies have compared the effects of individual OADs
on kidney function decline. A recent systematic review on the
‘Comparative Effectiveness and Safety of Oral Diabetes
Medications for Adults with Type 2 Diabetes’, sponsored by
the Agency for Healthcare Research and Quality, concluded
that there was insufﬁcient and low-quality evidence on the
effectiveness of individual OADs on the development or
progression of nephropathy.
13
The aim of this study was to determine whether initial
treatment with different OAD monotherapies was associated
with differential declines in kidney function. Using regional
Veterans Health Administration (VHA) data, we recently
reported that sulfonylurea users had worse kidney outcomes
than metformin users.
14 The aim of the present study was to
evaluate a larger national VHA cohort of OAD initiators, to
increase the precision of our estimates, and to extend our
assessment to include rosiglitazone.
RESULTS
Study cohort and analytic population
Of the 343,612 Type 2 DM veterans identiﬁed as incident
users of OADs (Figure 1), we excluded 24% for missing race,
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baseline estimated glomerular ﬁltration rate (eGFR)/
creatinine, 9% because of an eGFRo60 or a creatinine
41.5mg/dl, and 3% who were not on OAD monotherapy.
Of the 129,821 patients who met the eligibility criteria, 72%
(93,577) had complete baseline covariates and were included
in the ﬁnal analyses. Of those patients, 65% (61,104) initiated
metformin, 33% (30,550) initiated sulfonylureas, and 2%
(1923) initiated rosiglitazone. The characteristics of the
patients excluded from the analytical data set owing to
missing covariates were similar to the 72% included in the
analysis (Supplementary Table 1 online).
Patient characteristics
Baseline characteristics were similar across OAD groups
(Table 1). Overall, 78% were white, and 96% were men, and
median serum creatinine was 1.0mg/dl (interquartile range
(IQR)¼0.9, 1.1). Metformin initiators had the highest body
mass index median (32.3kg/m
2; IQR¼29, 37) compared
with rosiglitazone (31kg/m
2; IQR¼28, 35) and sulfonylurea
(31kg/m
2; 27, 35) initiators. Median HbA1c was lowest
among rosiglitazone (6.8; IQR¼6.2, 7.6) compared with
sulfonylurea (7.3; IQR¼6.6, 8.4) and metformin (7.1;
IQR¼6.5, 7.9) initiators. The median length of follow-up
by exposure group was 0.9 years for metformin (range¼
0.25–5.5 years/IQR¼0.5, 1.8), 0.8 years for sulfonylureas
(range¼0.25–5.5 years/IQR¼0.4–1.7), and 0.7 for rosiglita-
zone (range¼0.25–5.3/IQR¼0.3, 1.5). The percentage of
patients on angiotensin-converting enzyme (ACE) inhibitors
or angiotensin receptor blockers (ARBs) increased over time
and was similar across groups at baseline and during follow-
up (Figure 2).
Primary and secondary outcomes
The annual rate of the primary composite end point of a
persistent 25% decline in eGFR or ESRD was 3.8%, 5.0%,
and 3.2% in metformin, sulfonylurea, and rosiglitazone
initiators, respectively. eGFR events accounted for 97% of the
primary composite end points (97%, 97%, and 95% in the
metformin, sulfonylurea, and rosiglitazone initiators groups,
respectively). The annual rate of the secondary composite
end point, which included all-cause mortality, was 4.1, 5.5,
and 3.4% in the respective three OAD groups (Table 2).
Compared with metformin, sulfonylurea use was asso-
ciated with an increased risk of reaching the primary
composite end point (adjusted hazard ratio (aHR)¼1.20
(95% conﬁdence interval (CI): 1.13, 1.28)), as well as the
secondary outcome (aHR¼1.20 (95% CI: 1.13, 1.28)).
Compared with metformin, rosiglitazone use was not
signiﬁcantly associated with the primary or secondary
outcome (Table 2). We also made a direct comparison of
rosiglitazone and sulfonylurea use. Compared with sulfonyl-
ureas, rosiglitazone use was associated with a decreased
risk for both the primary (aHR¼0.76 (95% CI: 0.59, 0.99))
and secondary outcome (aHR¼0.73 (95% CI: 0.57, 0.94)).
Unadjusted cumulative incidence curves are shown in
Figure 2. The percentage of patients who remained at risk
at each time interval was similar across all exposure groups.
In addition, the percentage of patients who remained on ACE
inhibitors or ARBs was also similar.
343,612 Active VA users who fill an
incident OAD prescription
260,810 Active VA users who fill
incident OAD prescription
217,892 Eligible incident users with
a baseline creatinine
129,821 Active VA users who fill single-agent
OAD prescriptions eligible for analysis
Analytic sample
N=93,577 with complete covariates
Metformin
(N=61,104)
Sulfonylurea
(N=30,550)
Missing gender, date of birth, race, or age
< 18 years (N=82,802)
Excluded for serious medical illness
(N=42,918)
Excluded due to missing baseline eGFR
(N=45,761)
Excluded due to baseline creatinine >1.5 or
baseline GFR< 60 ml/min (N=31,294)
Excluded due to more than one
OAD (N=11,016)
Excluded for missing covariates or small N
Pioglitazone=434
Metformin=21,755
Sulfonylurea=13,075
Rosiglitazone=980
Rosiglitazone
(N=1923)
Figure 1|Flowchart of eligible patients. eGFR, estimated glomerular filtration rate; OAD, oral antidiabetic drug; VA, Veterans Affairs.
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Compared with metformin, sulfonylurea use (1 to 1 greedy
matching n¼57,904) was associated with an increased risk
for the primary outcome (aHR¼1.23 (95% CI: 1.15, 1.31);
Po0.0001); compared with metformin, rosiglitazone use (1
to 3 greedy matching n¼7648) was not statistically
associated with a higher or lower risk for the primary
outcome (aHR¼0.92 (95% CI: 0.67, 1.25); P¼0.59)).
Sensitivity analysis and subgroup analyses
Results were consistent with the primary analysis across all
sensitivity and subgroup analyses.
eGFR event defined as persistent 25% decline from baseline
eGFR and incident CKD (eGFRo60ml/min). When the require-
ment of achieving a GFRo60ml/min was added to the 25%
GFR decline, the number of events was substantially reduced
(from 4831 to 2332). However, results of this sensitivity
analysis were similar to those from the main analyses.
Sulfonylurea use was associated with a higher risk for both
the primary outcome (aHR¼1.17 (95% CI: 1.07, 1.27)) and
the secondary outcome (aHR¼1.17 (95% CI: 1.10, 1.25);
Po0.0001) compared with metformin. There were no
differences between rosiglitazone and metformin for either
the primary or secondary outcome.
The subset with baseline albumin to creatinine ratio (ACR)
measurement. Among the 15,065 patients with a baseline
Table 1|Baseline characteristics of the study cohort
Characteristics Metformin (N=61,104) Sulfonylurea (N=30,550) Rosiglitazone (N=1923)
Age, median (IQR, year) 60 (55, 69) 62 (56, 72) 64 (57,72)
Male, % 95 97 97
Race, %
White 79 76 72
Black 16 18 16
Hispanic 4 5 11
Other 1 1 1
Baseline creatinine, mg/dl, median (IQR) 1.0 (0.9, 1.1) 1.0 (0.9, 1.1) 1.0 (0.9, 1.1)
Glomerular filtration rate, ml/min 81 (72, 93) 80 (70, 93) 79 (69, 91)
Urine microalbumin–creatinine ratio test available, % 18 22 19
Microalbuminuria present, % 3 3 4
HbA1c, median (IQR) 7.1 (6.5, 7.9) 7.3 (6.6, 8.4) 6.8 (6.2, 7.6)
Systolic blood pressure, median (IQR) 134 (124, 144) 135 (124, 146) 133 (122, 143)
Diastolic blood pressure, median (IQR) 77 (70, 84) 76 (69, 84) 74 (67, 81)
Body mass index (kg/m
2), median (IQR) 32.3 (28.8, 36.7) 30.7 (27.3, 34.7) 30.9 (27.5, 34.7)
Coronary artery disease, % 21 23 23
Cerebrovascular disease, % 9 11 8
Peripheral vascular disease, % 3 3 3
Smoking, % 12 11 8
ACEI or ARBs, % 57 56 57
Thiazides, % 33 30 28
Loop diuretics, % 8 12 10
Statins, % 62 55 59
Number of outpatient medications, median (IQR) 5 (3, 8) 5 (3, 8) 5 (3, 7)
Number of outpatient visits, median (IQR) 5 (3, 8) 5 (3, 8) 4 (2, 7.5)
Hospitalized in the prior year, % 8 10 8
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; IQR, interquartile range.
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Figure 2|Crude cumulative incidence of the composite
outcome (persistent reduction of baseline estimated
glomerular filtration rate of 25% or end-stage renal disease
by oral antidiabetic drug exposure group).
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secondary end points were similar to those of the entire
cohort. Compared with metformin, sulfonylurea use was
associated with an increased risk of both the primary
(aHR¼1.22 (95% CI: 1.03, 1.44)) and secondary
(aHR¼1.20 (95% CI: 1.02, 1.481)) outcomes. There was
no signiﬁcant difference observed between rosiglitazone use
and metformin use for either the primary or the secondary
outcome (Table 2).
Persistent exposure not required. In this analysis, each
individual remained in their incident OAD regimen exposure
group throughout follow-up regardless of changes to their
regimen (similar to an intention-to-treat analysis). The
strength of the observed associations was attenuated but
consistent with the primary analysis such that sulfonylurea
use was associated with a higher risk of reaching the primary
outcome (aHR¼1.11 (95% CI: 1.06, 1.16)) and secondary
outcome (aHR¼1.13 (95% CI: 1.08, 1.18; Po0.0001))
compared with metformin. There were no differences
between the rosiglitazone therapy and metformin for either
the primary or the secondary outcome in this analysis
(Table 2).
Subgroup analyses. Prespeciﬁed assessments were per-
formed and no signiﬁcant interactions were identiﬁed bet-
ween OAD categories and the a priori subgroups: age,
race, use of ACE inhibitors/ARBs, and HbA1c levels (Figure 3).
Table 2|Event rates and adjusted hazard ratios for primary and secondary outcomes among incident OAD users
Metformin (N=61,104) Sulfonylurea (N=30,550) Rosiglitazone (N=1923)
Primary analysis–Persistent exposure required (PER)
a
Person time (years) 77,420 36,592 2014
Number of GFR or ESRD events 2926 1841 64
Rate/1000 person-years 3.8 5 3.2
aHR
b (95% CI) for the primary outcome Reference 1.20 (1.13, 1.28) 0.92 (0.71, 1.18)
Number of GFR, ESRD or death events 3149 2027 68
Rate/100 person-years 4.1 5.5 3.4
aHR
b (95% CI) for the secondary outcome Reference 1.20 (1.13, 1.28) 0.89 (0.69, 1.12)
Sensitivity analyses
PER with a more stringent definition of GFR event
c
Person time (years) 79,197 37,508 20,44
Number of GFR or ESRD events 1390 908 34
Rate/100 person-years 1.76 2.42 1.66
aHR
b (95% CI) for the primary outcome Reference 1.17 (1.07, 1.27) 0.90 (0.64, 1.27)
Number of GFR, ESRD or death events 1622 1102 38
Rate/1000 person-years 2.05 2.94 1.86
aHR
b (95% CI) for the secondary outcome Reference 1.16 (1.08, 1.27) 0.83 (0.60, 1.15)
PER adjusted for ACR 10,293 4366 401
Person Time (years) 12291 4959 415
Number of GFR or ESRD events 461 245 11
Rate/100 person-years 3.8 4.9 2.7
aHR
b (95% CI) for the primary outcome Reference 1.22 (1.03, 1.44) 0.67 (0.37, 1.25)
Number of GFR, ESRD, or death events 493 263 12
Rate/1000 person-years 4.0 5.3 2.9
aHR
b (95% CI) for the secondary outcome Reference 1.20 (1.02, 1.41) 0.70 (0.39, 1.24)
Persistent exposure not required (PENR)
d
Person time (years) 139,773 76,244 4492
Number of GFR or ESRD events 5752 3787 170
Rate/100 person-years 4.1 5.0 3.8
aHR
b (95% CI) for the primary outcome Reference 1.11 (1.06, 1.16) 1.01 (0.87, 1.18)
Number of GFR, ESRD, or death events 6403 4405 188
Rate/100 person-years 4.6 5.8 4.2
aHR
b (95% CI) for the secondary outcome Reference 1.13 (1.08, 1.18) 0.97 (0.84, 1.12)
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ACR, albumin to creatinine ratio; aHR, adjusted hazard ratio; ARB, angiotensin receptor blocker; BMI, body
mass index; CI, confidence interval; ESRD, end-stage renal disease; GFR, glomerular filtration rate; LDL, low-density lipoprotein; OAD, oral antidiabetic drug.
aPER: considers patients persistent on their incident regimen until they have a gap in use of medications that reaches 90 days, or have added or switched to a different OAD
or insulin, have a study outcome, have left the Veterans Affairs (VA), reached the end of the study or reached a creatinine of 1.5mg/dl or higher.
bCox proportional hazards model for time to renal disease. Adjusted hazard ratio is for each exposure compared with metformin as reference. All models were adjusted for
age, sex, race, fiscal year of cohort entry, number of medications, number of outpatient visits, history of hospitalization, baseline HbA1c, BMI, serum creatinine, LDL
cholesterol, use of medications (ACEI or ARBs, thiazide or loop diuretics, or statins), smoking-related illness, myocardial infarction; obstructive coronary disease, or prescription
for a long acting nitrate; stroke/transient ischemic attack; atrial fibrillation/flutter; mitral/aortic or rheumatic heart disease; asthma/obstructive pulmonary disease; procedures
for carotid/peripheral artery revascularization or bypass or lower extremity amputation. All continuous variables were modeled as third degree polynomials.
cGFR event defined as a persistent decline of 25% of baseline GFR plus reaching a GFRo60ml/min.
dPENR: patients remain in their initial OAD exposure group, regardless of their persistence on drug therapy, until a study outcome, or end of the study patients remain in their
original exposure group regardless of changes in therapy after cohort entry (akin to an intent to treat analysis).
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DM is the most common cause of CKD and progression to
ESRD in the United States.
2 Patients with CKD and ESRD
experience an increased risk of premature death even at early
disease stages.
3,4 In addition to the human costs, treatment
costs pose an enormous burden on the health-care system.
Although the efﬁcacy of OADs on glucose control is well
established,
13 their effects on long-term kidney function
outcomes are less clear.
13,15 Furthermore, whether individual
OADs have different effects on kidney function is unknown.
In this large national retrospective cohort study of 93,577
diabetic veterans initiating OAD monotherapy, initiation of
sulfonylureas compared with metformin was associated with
a 20% increased risk of the composite outcome of an eGFR
event or ESRD. This association was consistently observed
across all planned sensitivity analyses, including the use of a
more stringent GFR event deﬁnition, a subgroup analysis of
patients with baseline urine protein measurement, and an
analysis in which persistent exposure was not required.
Supplemental analyses using a propensity score–matched
design yielded almost identical results. These results are also
consistent with our previous ﬁndings in a smaller regional
VHA cohort from the southeast United States.
14
A number of renoprotective properties of metformin
have been recently recognized. Patients with CKD have
metabolic disturbances, including insulin resistance,
16–21
oxidative stress,
22 and chronic inﬂammation,
23–26 all of which
have been proposed to have a signiﬁcant role in CKD
progression.
18,27 Recent data indicate that metformin has
important antioxidant features
28 in addition to its known
insulin-sensitizing properties. Both of these properties are
relevant in early stages of diabetic kidney disease, when
beneﬁcial effects can be attained before the development of
irreversible glomerular damage. It is also possible that
different OADs confer a differential risk of acute renal injury
(AKI). Morales et al.
28 demonstrated in animal models that
metformin prevented gentamicin-induced AKI by normal-
izing oxidative stress and restoring mitochondrial functional
integrity. The contribution of AKI to CKD progression and
ESRD has recently been highlighted.
29,30 Thus, metformin
could slow CKD progression if it prevented or reduced the
severity of AKI.
Another possible explanation for the differences observed
is weight gain associated with sulfonylureas vs. metformin.
Excess weight has been recognized as a signiﬁcant risk factor
for CKD progression.
31–36 Multiple epidemiological and
mechanistic studies have conﬁrmed the adverse effects of
obesity on kidney function. The so-called ‘obesity glomer-
ulomegaly’ is primarily a model of hyper-ﬁltration associated
with the development of proteinuria. Sulfonylureas are well
known to promote weight gain.
15,32,34 In a systematic review,
the weighted mean absolute difference in body weight
between sulfonylureas and placebo in clinical trials was
3.8kg (3.6–4.0kg).
15 In a previous observational study in a
VHA regional cohort, the mean adjusted weight difference
between sulfonylurea users and metformin users at 12
months following initiation of treatment was 3.18kg.
37
Whether differences in weight gain among metformin
compared with sulfonylurea users could contribute to
differences observed in CKD and death requires further
scrutiny.
Recently, the United Kingdom Prospective Diabetes Study
(UKPDS)
38 10-year posttrial follow-up reported that sig-
niﬁcant risk reductions (¼0.79) persisted for any diabetes-
related end point (95% CI¼0.83–0.99) for metformin
compared with the dietary restriction group, but no
difference was observed in risk of microvascular disease
(including plasma creatinine or ACR). It is important to
highlight that in UKPDS patients were assigned to metformin
only if they were more than 120% of ideal body weight. Of
342 individuals randomized to metformin, only 136 (40%)
completed the posttrial monitoring. In the sulfonylurea vs.
dietary restriction arm, there was a 24% risk reduction for
any diabetes-related end point (P¼0.001), including renal
microvascular outcomes. Unlike UKPDS, we had sufﬁcient
power to directly compare metformin with sulfonylurea
therapy.
Our study found that rosiglitazone was associated with a
similar risk of kidney decline as metformin and lower risk
than sulfonylureas. Both metformin and rosiglitazone are
insulin sensitizers.
39 Previous studies found that rosiglitazone
decreased albuminuria in patients with DM.
11,12,40,41 Our
results are similar to those from the ADOPT clinical trial,
which reported a hazard ratio of 0.91 (95% CI: 0.67, 1.23) for
developing eGFR o60cc/min comparing rosiglitazone with
glyburide.
42 When using this same outcome, the aHR for the
same comparison in our cohort was 0.77 (95% CI: 0.55, 1.10;
data not shown). With the more sensitive deﬁnition requiring
65 years (n=36,534) 1.19 (1.08, 1.30)
1.21 (1.12, 1.32)
1.18 (0.99, 1.42)
1.21 (1.13, 1.29)
1.19 (1.10, 1.29)
1.20 (1.09, 1.32)
1.23 (1.14, 1.33)
1.14 (1.02, 1.26)
< 65 years (n=57,043)
Blacks (n=15,583)
Non-blacks (n=77,994)
HbA1c>7 (n=53,566)
HbA1c7 (n=43,868)
ACEi/ARBs (n=53,176)
Hazard ratio (95% CI)
0.75 1.00 1.25 1.50 0.50
Metformin Sulfonylurea
No ACEi/ARBs (n=40,401)
Figure 3|Adjusted hazard ratios for the composite
outcome of glomerular filtration rate event or end-stage
renal disease among age, race, HbA1c, and renin–angiotensin–
aldosterone system blockade subgroups. Hazard ratios greater
than 1 demonstrate an increased risk for composite outcome with
sulfonylurea compared with metformin. ACEi, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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difference in outcome was statistically signiﬁcant. Although
our study suggests that rosiglitazone does not differ from
metformin and is associated with slower decline in kidney
function compared with sulfonylureas, the sample size for the
rosiglitazone group was small, which limits the precision of
these estimates.
Our comparative effectiveness study has noteworthy
strengths. We assembled a large national cohort of diabetic
patients who allowed detection of small differences in risk.
This study applied a new-user design
43 and strict criteria to
minimize misclassiﬁcation of exposures, outcomes, and
covariates. Our analyses accounted for available laboratory
and physiological measurements that complemented admin-
istrative data, reducing concerns about residual confounding.
Our previous studies evaluating the associations between the
choice of ﬁrst OAD and intermediate outcomes, using a
regional VHA cohort, showed results consistent with those
from a recent systematic review on comparative effectiveness
and safety of medications for Type 2 diabetes.
13 Our group
estimated that after 1 year, compared with sulfonylurea use,
metformin initiators had 3.2kg lower weight; a nonsigniﬁ-
cant 5mg/dl lower low-density lipoprotein; 8.7mg/dl lower
triglycerides; and no difference in HbA1c.
37,44 The consis-
tency of our ﬁndings in the primary, secondary, and
sensitivity analyses, as well as with the small amount of
informative data from randomized clinical trials
42 and our
previous study using data from the southeastern region of
the United States,
14 lends further credibility to these results
and suggests a lack of systematic bias in the present cohort
study.
Although an intention-to-treat analysis is considered
the gold standard in clinical trials, trials are designed to
minimize non-adherence, crossover, and differential use of
co-therapies. We required persistent exposure on the OADs
of interest to best address the effect of these drugs. To
avoid confusion with clinical trials, we termed the analysis
that kept patients in their initial exposure group as persistent
exposure not required. In this analysis, the associations
we observed were similar to those of the primary analysis
but attenuated suggestive of increasing exposure misclassiﬁ-
cation.
If the observed more rapid decline in renal function
with sulfonylureas compared with metformin is indeed
causal, then our observed hazard ratio would mean that, in
clinical practice, for every 1000 patients begun on sulfonyl-
ureas rather than metformin therapy, an excess of about
8 persons annually will experience a 25% or more decline
in GFR.
Our study is not without limitations. First, although all
individuals had a GFR X60ml/min, there were no major
differences in measured characteristics between exposure
groups at baseline, and patients were censored after reaching
a serum creatinine X1.5mg/dl; confounding by indication is
still of concern if patients who initiated sulfonylurea or
metformin were systematically different in ways that make
them more likely to be diagnosed with kidney disease.
Second, our cohort consisted mainly of male veterans, and
ﬁndings should be generalized to other populations with
caution. Third, only a minority of the cohort had data on
proteinuria, a key predictor of CKD progression. The
subgroup analysis restricted to individuals with a baseline
measurement of urine protein strengthens our ﬁndings.
Fourth, in this retrospective study, some individuals with
reversible AKI may have been misclassiﬁed as having CKD
progression. We attempted to minimize such misclassiﬁca-
tion by requiring a conﬁrmatory eGFR measurement 3–12
months after the ﬁrst measurement.
Given the known limitations of using creatinine alone for
estimating kidney function,
45 we used eGFR (Modiﬁcation of
Diet in Renal Disease four-component equation) as the
measurement of kidney function, although it is less accurate
in a range of values 460ml/min. Nevertheless, we performed
a sensitivity analysis with a more stringent deﬁnition of eGFR
event, requiring not only a persistent 25% drop of baseline
eGFR but also reaching an eGFR p60ml/min, which should
mitigate these concerns. Finally, we used reﬁll data as a proxy
for medication exposure. Although exposure misclassiﬁca-
tion cannot be ruled out, our group has previously
demonstrated that prescription ﬁlls are a good proxy for
medication use, and we anticipate that this potential
misclassiﬁcation would be non-differential with regard to
exposure group, and thus would tend to bias our estimates
toward the null hypothesis.
37,44
In summary, in this large national retrospective cohort
study, initiation of sulfonylureas was associated with an
increased risk of a clinically signiﬁcant decline in kidney
function or death compared with initiation of metformin.
Our data support the current recommendations by the
American Diabetes Association and the International Dia-
betes Federation in their recommendation of metformin as
the ﬁrst-line therapy for DM, in patients with earlier stages of
kidney disease. More data are needed on risks and beneﬁts of
speciﬁc OADs in more advanced CKD.
MATERIALS AND METHODS
Study design and data sources
We conducted a retrospective cohort study of diabetic patients seen
within the VHA system between 1 October 2001 and 30 September
2008. The cohort was constructed using national VHA databases
from the Decision Support Services, which contain prescriptions
data and laboratory results. The primary source of the prescription
data was the Veterans Health Information System and Technology
Architecture (VistA) and included inpatient and outpatient
prescriptions dispensed by a VHA Pharmacy or a Consolidated
Mail Outpatient Pharmacy.
The VHA national medical data sets contain electronically
captured patient demographics and diagnostic and procedure
information from inpatient and outpatient encounters, coded
according to the International Classiﬁcation of Diseases, Ninth
Revision; Clinical Modiﬁcation (ICD9-CM). Data on vital signs
(blood pressure, weight, and height) and vital status were obtained
from the VHA Corporate Data Warehouse and Vital Status master
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University Medical Center and the VHATennessee Valley Healthcare
System (VHA TVHS) and the Research and Development
Committee of the VHA TVHS approved this study.
Study population
The study population included veterans X18 years old, who
received regular care in the VHA health-care system and ﬁlled an
incident OAD prescription during the study period. Incident
prescriptions were deﬁned as the ﬁrst OAD prescription ﬁlled after
365 days of active use of the VHA pharmacy services without any
antidiabetic drug ﬁlled.
43 Incident OAD users with known birth date
and gender, and at least 365 days of baseline data (for ascertainment
of other selection criteria and covariates), were included in our
cohort. Approximately 86% of our cohort members had a diabetes-
related ICD9-CM code within the 365 days preceding or at the time
of OAD initiation. We excluded patients with a baseline diagnosis
for serious medical conditions (congestive heart failure, HIV/AIDS,
cancer (except for non-melanoma skin cancer), transplant, end-
stage kidney or liver disease, or respiratory failure) or cocaine use,
as these conditions may inﬂuence the selection of antidiabetic
medications and affect the frequency of study outcomes. We also
excluded patients who had a baseline serum creatinine 41.5mg/dl
or with an eGFR o60ml/min, as these patients would be less likely
to be started on metformin. We excluded all patients missing race
information, as this is necessary for the calculation of eGFR using
the Modiﬁcation of Diet in Renal Disease equation.
Follow-up
Patients were followed up from the date of incident OAD prescription
ﬁll until development of the study outcome or a censoring event.
Censoring events were as follows: (1) leaving the VHA system, deﬁned
as 181 days of no contact with the VHA system; (2) the end of the
study (30 September 2008); (3) non-persistence on the incident OAD
regimen deﬁned as 90 days with no drug supply; switching or adding
another antidiabetic drug; and (4) the day after reaching a creatinine
value X1.5mg/dl. At these serum creatinine values, metformin is no
longer recommended,
46 and thus patients become less likely to
continue metformin treatment. Such selective dropout would create a
bias favoring metformin in these comparisons.
Exposure
The incident OAD monotherapy categories were metformin,
sulfonylurea, and rosiglitazone. Combination therapies and insulin
users during the baseline period were excluded because they often
represent regimen intensiﬁcation or persons with higher baseline
HbA1c. Pioglitazone was not in the Veterans Affairs formulary for
most of the study years, and hence the number of users was small
and excluded from further analyses.
Using pharmacy information, we calculated ‘days supply in
hand’. Given that patients may ‘stockpile’ medications, we estimated
how many pills a patient had on each follow-up day. For example, if
a patient ﬁlled a 90-day supply of metformin and reﬁlled it on day
80, then on day 80 the patient had 100 days supply in hand (90 from
the new ﬁll plus 10 leftover from initial ﬁll). Days supply in hand
was reset to 0 with a change in OAD dose. Initial dosing for the
different OADs is provided in the Supplementary Tables.
Outcomes
All eGFRs were estimated using the Modiﬁcation of Diet in
Renal Disease four-component equation.
37 High eGFR values were
truncated at 150ml/min. Serum creatinine levels o0.4mg/dl were
considered implausible and were excluded from the analysis.
The primary end point was a composite of a GFR event or
reaching ESRD. The secondary end point was a composite of GFR
event, ESRD, or all-cause mortality.
A GFR event was deﬁned as a persistent 25% or greater decline
from the baseline eGFR. This cutoff is clinically signiﬁcant and
similar to the one chosen by other studies that included this
higher range of eGFR values (incident or early CKD).
47–49 Because
the GFR event/ESRD deﬁnition was meant to capture CKD
progression, and not episodes of reversible AKI, we required that
the GFR event criteria also be met 3–12 months later. Persons
who were censored the day after a creatinine of 1.5mg/dl or greater
would be counted as having an outcome of interest if they met
criteria for a GFR event.
ESRD was deﬁned as reaching one of the following: an
eGFR o15ml/min per 1.73m
2 or the ﬁrst inpatient or outpatient
code for dialysis or related procedures or renal transplantation (see
Supplementary Information). We also required that ESRD criteria
(by eGFR or code) be met at 3–12 months to prevent capturing
reversible AKI episodes.
All-cause mortality was determined by a date of death in the
Veterans Affairs Vital Status Master ﬁle. Information from multiple
sources including Medicare, VHA utilization, Social Security, and
VHA compensation and pension beneﬁts is used to determine this
date and has been shown to be highly accurate when compared with
the National Death Index.
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Covariates
Important comorbidities were selected a priori and identiﬁed using
ICD9-CM–coded health-care encounters or prescriptions for speciﬁc
medications in the 365-day baseline period. The study covariates
included age, sex, race/ethnicity (white, black, Hispanic), year of
cohort entry, physiologic variables collected closest to cohort entry
(systolic and diastolic blood pressure, serum creatinine, HbA1c, and
body mass index), cardiovascular disease (coronary artery disease,
cardiovascular disease, and peripheral vascular disease), smoking,
chronic obstructive pulmonary disease, use of medications known to
affect creatinine values (ACE inhibitors or ARBs, loop and thiazide
diuretics), measures of health-care utilization including the number
of outpatient visits, hospitalization during the baseline period
(yes, no), and the unique number of prescription medications on
the index date, and Veterans Affairs site of incident care.
Information on baseline proteinuria was available in the form of
micro-ACR in a subset of patients (n¼15,065). Patients were
considered to have microalbuminuria if their ACR was X30mg/g.
Baseline creatinine was obtained exclusively from outpatient values.
Sensitivity and subgroup analyses
Sensitivity analyses included the following: (1) using a more
stringent deﬁnition of eGFR event, which required a GFRo60ml/
min in addition to 25% or more decline; (2) controlling for baseline
proteinuria, restricted to those with this measurement (n¼15,065);
and (3) not requiring persistent exposure to the initial OAD during
follow-up. This analysis is similar to an intention-to-treat analysis in
randomized trials.
Because of known differential effects of age, race, renin–angio-
tensin system blockade, and HbA1C on CKD progression, we
assessed for effect modiﬁcation through stratiﬁed analyses for age:
o65 years or X65 years, race: African American: yes/no, ACE
inhibitors/ARBs: yes/no, and HbA1c¼o7o r47. Age and HbA1c
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continuous variables in the main analysis.
Statistical analysis
The primary analysis was time to the renal composite end point
among those who persisted on their initial OAD. We evaluated time
to the ﬁrst of eGFR event or ESRD as the primary outcome, and an
eGFR event, ESRD, or death as the secondary outcome. In a
supplemental analysis, persistent exposure on the incident regiment
was not required. In addition, we performed propensity score–-
matched analyses for the primary outcome. The propensity score
models for sulfonylurea vs. metformin and rosiglitazone vs.
metformin yielded c statistics of 0.67 and 0.69, respectively,
reﬂecting that imbalance in baseline covariates was mild. Sulfonyl-
urea vs. metformin used a 1 to 1 greedy matching (N¼57,904) and
rosiglitazone vs. metformin a 1 to 3 greedy matching (N¼7648).
Cox proportional hazards regression models were used to analyze
the association between OAD regimen and time to the study
outcomes adjusting for the study covariates, and using metformin as
the reference for all comparisons. hazard ratio and 95% CI were
calculated. The proportional hazards assumption for the drug
groups was veriﬁed graphically and by testing for interactions with
drug group and time. There was no evidence of departure from
model assumptions. All continuous covariates were modeled with a
third-degree polynomial term to account for nonlinear effects.
Statistical analyses were conducted using R Statistical Program
(R Foundation, available at http://www.r-project.org) and SAS
for Windows 11.0 (SAS Institute, Cary, NC).
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